The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours

Tiffany Foo, David Goldstein, Eva Segelov, Jeremy Shapiro, Nick Pavlakis, Jayesh Desai, Desmond Yip, John Zalcberg, Timothy J. Price, Adnan Nagrial, Lorraine Chantrill, Matt Burge, Christos S. Karapetis, Niall Tebbutt, Amitesh C. Roy

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal tract mesenchymal tumours. Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced GIST. Imatinib was the first TKI to gain approval as management for patients with advanced GIST, establishing a new standard of care. Since then, as a result of several trials including the GRID and INVICTUS studies, we now have five lines of approved targeted therapy, including imatinib, sunitinib, regorafenib, ripretinib and avapritinib for the treatment of unresectable, advanced GISTs. In this review, the Australasian Gastrointestinal Trials Group (AGITG) provide an overview of the key trials that have changed clinical practice, discuss the molecular drivers of GISTs, the importance of molecular testing and directing therapy according to molecular targets, as well as future strategies in the management of advanced GISTs.

Original languageEnglish
Pages (from-to)95-110
Number of pages16
JournalTargeted Oncology
Volume17
Issue number2
Early online date15 Mar 2022
DOIs
Publication statusPublished - Mar 2022

Keywords

  • Gastrointestinal stromal tumours
  • Tyrosine kinase inhibitors
  • Patient outcomes

Fingerprint

Dive into the research topics of 'The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours'. Together they form a unique fingerprint.

Cite this